# Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

> **NCT03465540** · PHASE1 · TERMINATED · sponsor: **Amgen** · enrollment: 24 (actual)

## Conditions studied

- Multiple Myeloma
- Acute Myeloid Leukemia
- Non-Hodgkins Lymphoma
- Myelodysplastic Syndrome
- AML
- MDS
- NHL

## Interventions

- **DRUG:** AMG 397
- **DRUG:** Dexamethasone
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT03465540
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-17
- **Primary completion:** 2019-07-25
- **Final completion:** 2019-07-25
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Strategic decisions
- **Last updated:** 2023-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03465540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03465540, "Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03465540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*